A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KZR-616 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs KZR 616 (Primary) ; KZR 616 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Kezar Life Sciences
- 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 31 Oct 2017 According to a Kezar Life Sciences media release, data from the study will be presented at the 2017 American College of Rheumatology Annual Meeting.
- 30 Aug 2017 Status changed from recruiting to completed.